1. Kajander EO, Ciftcioglu N. Nanobacteria: an
alternative mechanism for pathogenic intra– and
extracellular calcification and stone formation. Proc
Natl Acad Sci U S A 1998; 95(14):8274–8279.
2. Urbano P, Urbano F. Nanobacteria: facts or fancies?
PLoS Pathog 2007; 3(5):e55.
3. Young JD, Martel J, Young L et al. Putative
nanobacteria represent physiological remnants and
culture by–products of normal calcium homeostasis.
PLoS One 2009; 4(2):e4417.
4. Kajander EO, Ciftcioglu N, Aho K et al.
Characteristics of nanobacteria and their possible role
in stone formation. Urol Res 2003; 31(2):47–54.
5. Sommer AP, Oron U, Pretorius AM et al. A
preliminary investigation into light–modulated
replication of nanobacteria and heart disease. J Clin
Laser Med Surg 2003; 21(4):231–235.
6. Martel J, Wu CY, Young JD. Critical evaluation
of gamma–irradiated serum used as feeder in the
culture and demonstration of putative nanobacteria
and calcifying nanoparticles. PLoS One 2010;
5(4):e10343.
7. Young JD, Martel J. The rise and fall of nanobacteria.
Sci Am 2010; 302(1):52–59.
8. Socransky SS, Haffajee AD. Dental biofilms: difficult
therapeutic targets. Periodontol 2000 2002; 28:12–55.
9. Abraham J, Grenon M, Sanchez HJ et al. A case study
of elemental and structural composition of dental
calculus during several stages of maturation using
SRXRF. J Biomed Mater Res A 2005; 75(3):623–
628.
10. Demir T. Is there any relation of nanobacteria
with periodontal diseases? Med Hypotheses 2008;
70(1):36–39.
11. Zhang SM, Tian F, Jiang XQ et al. Evidence for
calcifying nanoparticles in gingival crevicular fluid
and dental calculus in periodontitis. J Periodontol
2009; 80(9):1462–1470.
12. Abraham J, Grenon M, Sanchez HJ et al.
Spectrochemical analysis of dental calculus by
synchrotron radiation X–ray fluorescence. Anal
Chem 2002; 74(2):324–329.
13. White DJ. Dental calculus: recent insights into
occurrence, formation, prevention, removal and
oral health effects of supragingival and subgingival
deposits. Eur J Oral Sci 1997; 105(5 Pt 2):508–522.
14. Hung HC, Willett W, Merchant A et al. Oral health
and peripheral arterial disease. Circulation 2003;
107(8):1152–1157.
15. Higashi Y, Goto C, Hidaka T et al. Oral infection–
inflammatory pathway, periodontitis, is a risk factor
for endothelial dysfunction in patients with coronary
artery disease. Atherosclerosis 2009; 206(2):604–
610.
16. Ford PJ, Raphael SL, Cullinan MP et al. Why should
a doctor be interested in oral disease? Expert Rev
Cardiovasc Ther 2010; 8(10):1483–1493.
17. Cotti E, Dessi C, Piras A et al. Can a chronic dental
infection be considered a cause of cardiovascular
disease? A review of the literature. Int J Cardiol 2011;
148(1): 4–10.
18. Hayashi C, Gudino CV, Gibson FC, 3rd et al. Review:
Pathogen–induced inflammation at sites distant from
oral infection: bacterial persistence and induction of
cell–specific innate immune inflammatory pathways.
Mol Oral Microbiol 2010; 25(5):305–316.
19. Zaremba M, Gorska R, Suwalski P et al. Evaluation
of the incidence of periodontitis–associated bacteria
in the atherosclerotic plaque of coronary blood
vessels. J Periodontol 2007; 78(2):322–327.
20. Carallo C, Fortunato L, de Franceschi MS et al.
Periodontal disease and carotid atherosclerosis: are
hemodynamic forces a link? Atherosclerosis 2010;
213(1):263–267.
21. Nakib SA, Pankow JS, Beck JD et al. Periodontitis
and coronary artery calcification: the Atherosclerosis
Risk in Communities (ARIC) study. J Periodontol
2004; 75(4):505–510.
22. Ciftcioglu N, McKay DS, Kajander EO. Association
between nanobacteria and periodontal disease.
Circulation 2003; 108(8):e58–9; author reply e58–59.
23. Miller VM, Rodgers G, Charlesworth JA et al.
Evidence of nanobacterial–like structures in calcified
human arteries and cardiac valves. Am J Physiol
Heart Circ Physiol 2004; 287(3):H1115–1124.
24. Puskas LG, Tiszlavicz L, Razga Z et al. Detection of
nanobacteria–like particles in human atherosclerotic
plaques. Acta Biol Hung 2005; 56(3–4):233–245.
25. Jelic TM, Malas AM, Groves SS et al. Nanobacteria–
caused mitral valve calciphylaxis in a man with
diabetic renal failure. South Med J 2004; 97(2):194–
198.
26. Hu YR, Zhao Y, Sun YW et al. Detection of
nanobacteria–like material from calcified cardiac
valves with rheumatic heart disease. Cardiovasc
Pathol 2010; 19(5):286–292.
27. Nadeem M, Stephen L, Schubert C et al. Association
between periodontitis and systemic inflammation in
patients with end–stage renal disease. SADJ 2009;
64(10):470–473.
28. Dag A, Firat ET, Kadiroglu AK et al. Significance
of elevated gingival crevicular fluid tumor necrosis
factor–alpha and interleukin–8 levels in chronic
hemodialysis patients with periodontal disease. J
Periodontal Res 2010; 45(4):445–450.
29. Madore F. Periodontal disease: a modifiable risk
factor for cardiovascular disease in ESRD patients?
Kidney Int 2009; 75(7):672–674.
30. Kshirsagar AV, Offenbacher S, Moss KL et al.
Antibodies to periodontal organisms are associated
with decreased kidney function. The Dental
Atherosclerosis Risk In Communities study. Blood
Purif 2007; 25(1):125–132.
31. Khullar M, Sharma SK, Singh SK et al. Morphological
and immunological characteristics of nanobacteria
from human renal stones of a north Indian population.
Urol Res 2004; 32(3):190–195.
32. Hjelle JT, Miller–Hjelle MA, Poxton IR et al.
Endotoxin and nanobacteria in polycystic kidney
disease. Kidney Int 2000; 57(6):2360–2374.
33. Shiekh FA, Khullar M, Singh SK. Lithogenesis:
induction of renal calcifications by nanobacteria.
Urol Res 2006; 34(1):53–57.
34. Kajander EO, Ciftcioglu N, Miller–Hjelle MA
et al. Nanobacteria: controversial pathogens in
nephrolithiasis and polycystic kidney disease. Curr
Opin Nephrol Hypertens 2001; 10(3):445–452.
35. 35. Shoskes DA, Thomas KD, Gomez E. Anti–
nanobacterial therapy for men with chronic prostatitis/
chronic pelvic pain syndrome and prostatic stones:
preliminary experience. J Urol 2005; 173(2):474–
477.
36. Zhou Z, Hong L, Shen X et al. Detection of
nanobacteria infection in type III prostatitis. Urology
2008; 71(6):1091–1095.
37. de Pablo P, Chapple IL, Buckley CD et al. Periodontitis
in systemic rheumatic diseases. Nat Rev Rheumatol
2009; 5(4):218–224.
38. Berthelot JM, Le Goff B. Rheumatoid arthritis
and periodontal disease. Joint Bone Spine 2010;
77(6):537–541.
39. Ogrendik M. Rheumatoid arthritis is linked to oral
bacteria: etiological association. Mod Rheumatol
2009; 19(5):453–456.
40. Bozkurt FY, Yetkin Ay Z, Berker E et al. Anti–
inflammatory cytokines in gingival crevicular fluid in
patients with periodontitis and rheumatoid arthritis: a
preliminary report. Cytokine 2006; 35(3–4):180–185.
41. Tsurumoto T, Matsumoto T, Yonekura A et al.
Nanobacteria–like particles in human arthritic
synovial fluids. J Proteome Res 2006; 5(5):1276–
1278.
42. Eskandary H, Saba M, Yazdi T. Nanobacteria and
intervertebral disc degeneration. Med Hypotheses
2005; 65(5):997–998.
43. Smolik I, Robinson D, El–Gabalawy HS. Periodontitis
and rheumatoid arthritis: epidemiologic, clinical, and
immunologic associations. Compend Contin Educ
Dent 2009; 30(4):188–90, 192, 194 passim; quiz 198,
210.
44. Cappuyns I, Gugerli P, Mombelli A. Viruses in
periodontal disease – a review. Oral Dis 2005;
11(4):219–229.
45. Gonzalez OA, Ebersole JL, Huang CB. Oral
infectious diseases: a potential risk factor for HIV
virus recrudescence? Oral Dis 2009; 15(5):313–327.
46. Mataftsi M, Skoura L, Sakellari D. HIV infection
and periodontal diseases: an overview of the post–
HAART era. Oral Dis 2011;17(1): 13–25.
47. Pretorius AM, Sommer AP, Aho KM et al. HIV and
nanobacteria. HIV Med 2004; 5(6):391–393.
48. Sommer AP. Peripheral neuropathy and light–
preliminary report indicating prevalence of
nanobacteria in HIV. J Proteome Res 2003; 2(6):665–
666.
49. Sommer AP. Could reduced bone mineral densities
in HIV be caused by nanobacteria? J Proteome Res
2004; 3(3):670–672.
50. Cisar JO, Xu DQ, Thompson J et al. An
alternative interpretation of nanobacteria–induced
biomineralization. Proc Natl Acad Sci U S A 2000;
97(21):11511–11515.
Thank you for copying data from http://www.arastirmax.com
